LINC01590: A Potential Drug Target and Biomarker (G63914)

Target Name: LINC01590

NCBI ID: G63914

LINC01590

Other Name(s): Long intergenic non-protein coding RNA 1590 | C6orf164 | dJ102H19.4 | long intergenic non-protein coding RNA 1590

LINC01590: A Potential Drug Target and Biomarker

Non-protein-coding RNAs (NP-ncRNAs) have emerged as a promising candidate for drug targeting and biomarker discovery due to their diverse functions in various cellular processes. One of these NPs, LINC01590, has shown promise in modulating the expression of genes involved in cell adhesion, migration, and invasion, providing a potential target for the development of new pharmaceuticals and diagnostic tools.

LINC01590 is a long intergenic non-protein-coding RNA (lncRNA) with a length of approximately 290 nucleotides. It is located between exons 18 and 19 of chromosome 6 and is expressed in various tissues, including fetal brain, heart, and liver. LINC01590 is characterized by a unique open reading frame (ORF) that includes a unique start codon, a second start codon, and a termination codon, indicating that it is a functional RNA molecule.

Several studies have identified LINC01590 as a potential drug target in various organisms. For instance, LINC01590 has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes for the development and progression of various diseases, including cancer.

One of the key functions of LINC01590 is its role in the regulation of tight junctions, which are a type of cell-cell adhesion that helps maintain tissue structure and prevent the excessive migration of cells. The LINC01590 gene has been shown to encode a protein that is involved in the formation and maintenance of tight junctions.

In addition to its role in cell adhesion and migration, LINC01590 has also been shown to be involved in the regulation of cell survival and angiogenesis, processes that are critical for the development and progression of various diseases, including cancer.

The expression of LINC01590 has been shown to be regulated by various factors, including cell cycle, apoptosis, and signaling pathways. For example, LINC01590 has been shown to be involved in the regulation of the cell cycle, with studies showing that it is involved in the G1 phase and the S phase of the cell cycle.

Furthermore, LINC01590 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. Studies have shown that LINC01590 can induce apoptosis in various cell types and that it is involved in the regulation of cell apoptosis.

In addition to its role in cell cycle and apoptosis, LINC01590 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. Studies have shown that LINC01590 can promote the formation of blood vessels in various tissues and that it is involved in the regulation of angiogenesis.

The potential drug targeting of LINC01590 is based on its unique function as a non-protein-coding RNA and its role in various cellular processes. The identification of LINC01590 as a potential drug target has led to a growing body of research aimed at understanding its functions and the mechanisms involved in its regulation.

In conclusion, LINC01590 is a long intergenic non-protein-coding RNA that has shown promise as a potential drug target and biomarker. Its unique function as a non-protein-coding RNA and its involvement in various cellular processes make it an attractive target for further investigation and development. Further studies are needed to fully understand the mechanisms involved in the regulation of LINC01590 and its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 1590

The "LINC01590 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01590 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets